Milestone Pharmaceuticals is trading at $0.71, down 10.61%, as broader market weakness coincides with the decline; no company-specific catalyst is confirmed.
- No company-specific announcement was identified for October 16; the latest highlighted trial news predates the decline.
- Reuters reported U.S. stocks lower amid higher-rate concerns and tech-led selling, providing market context but not establishing a direct cause for Milestone Pharmaceuticals.